Small-molecule inhibitors of cell signaling

Current Opinion in Biotechnology

Volumn 11, Issue 6, 2000, Pages 593-597

  McCormick, Frank ^a  

^a Cancer Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BCR ABL PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR; GEFITINIB; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; PD 15870; PHOSPHATIDYLINOSITOL KINASE; PROTEIN BCL 2; PROTEIN KINASE INHIBITOR; PROTEIN MDM2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; CANCER SURVIVAL; CANCER THERAPY; ENZYME INHIBITOR INTERACTION; GENE TARGETING; GENE THERAPY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033636402     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(00)00149-X     Document Type: Review

References (49)

1. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis
2. Essential role for oncogenic Ras in tumour maintenance
3. Ras oncogenes in human cancer: A review
4. PIK3CA is implicated as an oncogene in ovarian cancer
5. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras
6. The multiple roles of PTEN in tumor suppression
7. Defects in the regulation of beta-catenin in colorectal cancer
8. Molecular mechanisms of Bcr-Abl-induced oncogenesis
9. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors
10. Protein tyrosine kinases and cancer
11. TGF-beta signaling, Smads, and tumor suppressors
12. Cancer cell cycles
13. Tumor surveillance via the ARF-p53 pathway
14. BCL-2 gene family and the regulation of programmed cell death
15. Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis
16. Mechanism-based target identification and drug discovery in cancer research
17. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo
18. c-fos is required for malignant progression of skin tumors
19. Cyclin D1 provides a link between development and oncogenesis in the retina and breast
20. Fos and bone cell development: Lessons from a nuclear oncogene
21. K-ras is an essential gene in the mouse with partial functional overlap with N-ras
22. Guanosine triphosphatase stimulation of oncogenic Ras mutants
23. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
24. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
25. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
26. The retinoblastoma gene family in differentiation and development
27. A matter of life and cell death
28. Evidence for a function of death-receptor-related, death-domain-containing proteins in anoikis
29. Involvement of FADD and caspase-8 signalling in detachment-induced apoptosis
30. Antiangiogenic agents
31. Incipient angiogenesis
32. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
33. A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein beta gamma subunits
34. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
35. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration
36. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor
37. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines
38. GTP-binding proteins. Structures, interactions and relationships
39. Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target
40. CDK inhibition and cancer therapy
41. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases
42. Inhibition of p38 MAP kinase as a therapeutic strategy
43. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo
44. Identification of a novel inhibitor of mitogen-activated protein kinase kinase
45. Interactions between Ras proteins and their effectors
46. The 2.2 Å crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue
47. Target-oriented and diversity-oriented organic synthesis in drug discovery
48. Brefeldin A: The advantage of being uncompetitive
49. Affinity modulation of small-molecule ligands by borrowing endogenous protein surfaces